Canadian Cannabis Brand Scale And EU GMP Plans Will Shape Future Earnings Potential

Catalysts

About Auxly Cannabis Group

Auxly Cannabis Group is a Canadian cannabis company focused on branded products across dried flower, pre rolls and vapes, supported by cultivation and processing operations at Auxly Leamington.

What are the underlying business or industry changes driving this perspective?

• Back Forty holding the position as the number one cannabis brand in Canada by dollars sold, with leading products in dried flower, pre rolls and vapes, gives Auxly brand scale in categories that are expected to remain core for adult use cannabis. This can support sustained net revenue growth and brand driven pricing power.
• Investment of about $10 million to $12 million of operating cash flow into a world class post harvest environment at Auxly Leamington, including state of the art drying, curing, processing and packaging, is aimed at higher quality, more capacity and lower COGS. This can support gross margin and EBITDA margin over time.
• Expansion of Canadian distribution, with products now available in about 97% of retail locations and an explicit focus on "winning at home," positions Auxly to benefit from ongoing consumer shift from illicit to legal channels and growing demand for value focused products. This can support net revenue and cash flow from operations.
• Progress toward EU GMP capable infrastructure and the intention to build international direct shipment capabilities, while testing overseas markets with small shipments, positions Auxly to participate if medical or adult use markets abroad open further. This could add new revenue streams and support earnings over the longer term.
• Consistent emphasis on efficiency, automation, procurement, product mix and cost control, combined with using operating cash flow for capital projects and potential acquisitions like Ayurcann, points to a model that targets high cash flow conversion and disciplined capital deployment. This can influence net income, free cash flow and balance sheet strength.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Auxly Cannabis Group's revenue will grow by 6.6% annually over the next 3 years.
• Analysts assume that profit margins will shrink from 27.6% today to 7.2% in 3 years time.
• Analysts expect earnings to reach CA$13.2 million (and earnings per share of CA$0.0) by about March 2029, down from CA$41.9 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 33.0x on those 2029 earnings, up from 4.7x today. This future PE is greater than the current PE for the CA Pharmaceuticals industry at 11.6x.
• Analysts expect the number of shares outstanding to grow by 2.47% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.25%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The Canadian recreational cannabis market is expected by management to grow about 5%, so Auxly's goal of growing net revenue above that rate relies on maintaining share gains in core categories. If competitors match Auxly's product quality or pricing, revenue growth and EBITDA could slow.
• The business model is heavily tied to value focused products such as Back Forty. If consumer preferences shift away from value offerings or if price competition intensifies in that segment, this could pressure net revenue, gross margin and EBITDA margin.
• The plan to build EU GMP capable infrastructure and test international markets assumes that overseas channels eventually support direct shipments. If regulatory frameworks or demand abroad do not develop as expected, the related capital expenditures may dilute returns and weigh on free cash flow and earnings.
• Auxly intends to allocate $10 million to $12 million of operating cash flow annually into Auxly Leamington and may pursue acquisitions like Ayurcann. If these projects fail to deliver efficiency gains or category benefits in line with expectations, return on invested capital, free cash flow and net income could be weaker than hoped.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of CA$0.25 for Auxly Cannabis Group based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CA$183.6 million, earnings will come to CA$13.2 million, and it would be trading on a PE ratio of 33.0x, assuming you use a discount rate of 6.3%.
• Given the current share price of CA$0.14, the analyst price target of CA$0.25 is 44.0% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.